Search bioRxiv⌕ Search

Biology subjects

Majid, S.

Publications and source records attributed to Majid, S..

3 recordsLinked to original sources

omicML: An Integrative Bioinformatics and Machine Learning Framework for Transcriptomic Biomarker Identification

IntroductionTranscriptomic biomarker discovery has been a challenge due to variation in datasets and platforms, complexity in statistical and computational methods, integration of multiple programming languages, and intricacy of ML workflow to evaluate biomarkers. Standard workflows necessitate several stages (quality control, normalization, differential expression), typically executed in R or Python, resulting in bottlenecks for non-experts. Existing platforms have alleviated certain challenges by offering graphical interfaces for data loading, normalization, differential gene expression analysis, and functional analysis; nevertheless, they typically do not incorporate integrated machine learning procedures for biomarker selection. MethodIn this regard, we present omicML, an intuitive graphical user interface (GUI) that combines transcriptomic data analysis with machine learning (ML)-based classification via integrating R and Python packages/libraries. It supports both RNA-Seq and microarray data, automating preprocessing (data import, quality control, and normalization) and differential expression analysis. The tool annotates differentially expressed genes (DEGs) with descriptions, gene ontology, and pathway information and incorporates comparative analysis. Our extensive ML pipeline enables both supervised and unsupervised learning, integrates various datasets based on candidate gene signatures, standardizes and eliminates less significant features, benchmarks multiple ML classifiers with robust performance metrics (e.g., AUROC, AUPRC), assesses feature importance, develops single-gene and multi-gene predictive models, and systematically finalizes the biomarker algorithm. All functionalities are available in omicML, hence reducing the barrier for biologists without computational proficiency. ResultIn a case study, omicML identified a six-gene diagnostic model that distinguishes Mpox (monkeypox virus) infections from those caused by other viruses, including SARS-CoV-2, HIV, Ebola, and varicella-zoster. These results illustrate omicMLs capacity to discern clinically relevant biomarkers from complex transcriptome data. ConclusionThrough the unified system, omicML (https://omicml.org), integrating data preprocessing, differential gene expression analysis, annotation, heatmap analysis, dataset integration, batch effect correction, machine learning approach, and functional analysis can diminish technical barriers and accelerates the conversion of expression data into diagnostic insights for clinicians and bench scientists.

bioinformatics↗

Phospholipid Scramblase 1 (PLSCR1) Regulates Interferon-Lambda Receptor 1 (IFN-lambdaR1) and IFN-lambda Signaling in Influenza A Virus (IAV) Infection

Phospholipid scramblase 1 (PLSCR1) is an antiviral interferon-stimulated gene (ISG) that has several known anti-influenza functions. However, the mechanisms in relation to its expression compartment and enzymatic activity have not been completely explored. Moreover, only limited animal models have been studied to delineate its role at the tissue level in influenza infections. Our results showed that Plscr1 expression was highly induced by influenza A virus (IAV) infection in vivo and in airway epithelial cells treated with IFN-{lambda}. We found that infected Plscr1-/-mice exhibited exacerbated body weight loss, decreased survival rates, heightened viral replication, and increased lung damage. Interestingly, transcriptomic analyses demonstrated that Plscr1 was required for the expression of type 3 interferon receptor (Ifn-{lambda}r1) and a large subset of ISGs upon IAV infection. The impaired expression of Ifn-{lambda}r1 and downstream ISGs may be responsible for delayed viral clearance and worse lung inflammation in Plscr1-/- mice. PLSCR1 acts as a transcriptional activator of IFN-{lambda}R1 by directly binding to its promotor after IAV infection. In addition, PLSCR1 interacted with IFN-{lambda}R1 on the cell surface of pulmonary epithelial cells following IAV infection, suggesting it also modulated IFN-{lambda} signaling via protein-protein interactions. The lipid scramblase activity of PLSCR1 was found to be dispensable for its anti-flu activity. Finally, single-cell RNA sequencing data indicated that Plscr1 expression was significantly upregulated in ciliated airway epithelial cells in mice following IAV infection. Consistently, Plscr1floxStopFoxj1-Cre+ mice with ciliated epithelial cell-specific Plscr1 overexpression showed reduced susceptibility to IAV infection, less inflammation and enhanced Ifn-{lambda}r1 expression, suggesting that Plscr1 primarily regulates type 3 IFN signaling as a cell intrinsic defense factor against IAV in ciliated airway epithelial cells. Our research will elucidate virus-host interactions and pave the way for the development of novel anti-influenza drugs that target human elements like PLSCR1, thereby mitigating the emergence of drug-resistant IAV strains.

immunology↗

Seroprevalence of SARS-CoV-2 specific IgG antibodies in District Srinagar, northern India - a cross-sectional study

BackgroundPrevalence of IgG antibodies against SARS-CoV-2 infection provides essential information for deciding disease prevention and mitigation measures. We estimate the seroprevalence of SARS-CoV-2 specific IgG antibodies in District Srinagar. Methods2906 persons >18 years of age selected from hospital visitors across District Srinagar participated in the study. We tested samples for the presence of SARS-CoV-2 specific IgG antibodies using a chemiluminescent microparticle immunoassay-based serologic test. ResultsAge- and gender-standardized seroprevalence was 3.6% (95% CI 2.9% to 4.3%). Age 30-69 years, a recent history of symptoms of an influenza-like-illness, and a history of being placed under quarantine were significantly related to higher odds of the presence of SARS-CoV-2 specific IgG antibodies. The estimated number of SARS-CoV-2 infections during the two weeks preceding the study, adjusted for test performance, was 32602 with an estimated (median) infection-to-known-case ratio of 46 (95% CI 36 to 57). ConclusionsThe seroprevalence of SARS-CoV-2 specific IgG antibodies is low in the District. A large proportion of the population is still susceptible to the infection. A sizeable number of infections remain undetected, and a substantial proportion of people with symptoms compatible with COVID-19 are not tested.

immunology↗